# TAU G272V Research Report **Protein:** TAU G272V **Variant:** G272V **UniProt ID:** P10636 **Disease Association:** Alzheimer's disease **Report Generated:** 2026-07-26 13:03 UTC **AlphaFold Confidence (pLDDT):** 55.0% **Structure Folded:** 2026-06-21 --- ## Structure Summary The tau protein normally helps stabilize the internal scaffolding of brain cells, but in Alzheimer's disease it forms toxic clumps that damage neurons. Scientists used AlphaFold2 to predict the three-dimensional structure of tau containing the G272V mutation (where glycine at position 272 is replaced by valine), but the resulting model had very low confidence (average score of 55 out of 100), indicating the prediction is too uncertain to draw reliable conclusions about how this specific mutation affects tau's structure or its role in disease. --- Tau is a microtubule-associated protein that normally helps maintain the structural integrity of neurons by stabilizing microtubules, the internal scaffolding that supports cell shape and transports materials within cells [1]. In Alzheimer's disease and related tauopathies, tau undergoes abnormal aggregation into beta-sheet-rich fibrillar structures that accumulate in brain tissue and contribute to neurodegeneration [1]. Understanding how specific mutations affect tau structure could provide insights into disease mechanisms, though this requires high-quality structural data. The G272V variant involves replacing glycine, a small flexible amino acid, with valine, a larger branched amino acid, at position 272 of the tau protein. This structural prediction analysis used AlphaFold2, a machine learning-based method for predicting protein structures from amino acid sequences. However, the resulting model achieved an average confidence score (pLDDT) of only 55 out of 100, which falls well below the threshold of 70 generally considered necessary for reliable structural interpretation. This low confidence indicates that the prediction should not be trusted to accurately represent the actual three-dimensional structure of tau G272V. The extremely low confidence likely reflects inherent challenges in modeling tau's structure. Tau contains large intrinsically disordered regions that lack stable three-dimensional structure under physiological conditions, existing instead as flexible ensembles of conformations [1]. AlphaFold2 and similar methods perform poorly on such disordered proteins because they are trained primarily on well-folded protein structures. Additionally, tau's structure is context-dependent: it adopts different conformations when bound to microtubules versus when aggregated into pathological fibrils [1], making it difficult to predict a single representative structure. Without reliable structural data, it is not possible to determine whether the G272V mutation affects tau's normal microtubule-binding function, its propensity to aggregate into disease-associated fibrils, or its interactions with other cellular components. Experimental approaches such as solid-state NMR spectroscopy have proven valuable for characterizing both fibrillar tau assemblies and membrane-bound tau involved in aggregation and intercellular transmission [1], and such methods would be necessary to properly evaluate the structural and functional consequences of this variant. Clinical studies using biomarkers like plasma phosphorylated tau (p-tau181, p-tau217, p-tau231) have shown promise for diagnosing Alzheimer's disease and distinguishing it from other neurodegenerative conditions [2], though the specific pathogenic role of G272V remains to be established. ## Works Cited [1] El et al. (2026). Structures and Dynamics of Tau Assemblies from Solid-State NMR. Accounts of chemical research. [PubMed](https://pubmed.ncbi.nlm.nih.gov/42283695/) [2] Chai et al. (2026). Plasma p-tau as a biomarker for the differential diagnosis of Alzheimer's disease: a systematic review and meta-analysis. Alzheimer's research & therapy. [PubMed](https://pubmed.ncbi.nlm.nih.gov/42252466/) ## Similar Research **Biomarker discovery in Alzheimer's and neurodegenerative diseases using Nucleic Acid Linked Immuno-Sandwich Assay.** Ashton et al. (2025) *Relevant to Alzheimer's disease research* [Read on PubMed](https://pubmed.ncbi.nlm.nih.gov/40401628/) **Proteomic analysis reveals distinct cerebrospinal fluid signatures across genetic frontotemporal dementia subtypes.** Sogorb-Esteve et al. (2025) *Relevant to Alzheimer's disease research* [Read on PubMed](https://pubmed.ncbi.nlm.nih.gov/39908349/) **Protein quality control systems in neurodegeneration - culprits, mitigators, and solutions?** Ciechanover et al. (2025) *Relevant to Alzheimer's disease research* [Read on PubMed](https://pubmed.ncbi.nlm.nih.gov/40969213/) **Melatonin-Mediated Nrf2 Activation as a Potential Therapeutic Strategy in Mutation-Driven Neurodegenerative Diseases.** Inigo-Catalina et al. (2025) *Relevant to Alzheimer's disease research* [Read on PubMed](https://pubmed.ncbi.nlm.nih.gov/41154499/) **Alzheimer's Disease Continuum: Evaluating the Relationship between Fluid Biomarkers and Patients' Phenotype and Profile.** Gerlando et al. (2026) *Relevant to Alzheimer's disease research* [Read on PubMed](https://pubmed.ncbi.nlm.nih.gov/41619269/) --- ## Open Targets Disease Associations | Disease | Score | Data Sources | |---------|-------|--------------| | frontotemporal dementia | 0.789 | genetic_literature, clinical, literature, genetic_association, animal_model | | Pick disease | 0.757 | literature, animal_model, genetic_association, genetic_literature | | supranuclear palsy, progressive, 1 | 0.725 | literature, animal_model, genetic_association, genetic_literature | | Progressive supranuclear palsy - parkinsonism | 0.715 | literature, animal_model, genetic_association, genetic_literature | | Atypical progressive supranuclear palsy | 0.715 | literature, animal_model, genetic_association, genetic_literature | | Classical progressive supranuclear palsy | 0.696 | literature, animal_model, genetic_association, genetic_literature | | progressive supranuclear palsy-parkinsonism syndrome | 0.647 | animal_model, genetic_association, genetic_literature | | late-onset Parkinson disease | 0.639 | literature, animal_model, genetic_association, genetic_literature | | semantic dementia | 0.639 | literature, animal_model, genetic_association, genetic_literature | | progressive supranuclear palsy | 0.614 | genetic_literature, clinical, literature, genetic_association, animal_model | *...and 3339 more associations* --- ## AI Research Brief # Research Brief: TAU G272V Variant ## Pathogenic Mechanisms The TAU G272V variant represents a relatively understudied mutation in the microtubule-associated protein tau (MAPT), with limited direct literature available on this specific substitution. The glycine-to-valine substitution at position 272 occurs within a functionally critical region of tau that contributes to its microtubule-binding properties and conformational flexibility. Given tau's known molecular functions including actin binding, apolipoprotein binding, and DNA binding, the G272V mutation likely disrupts protein structure through the introduction of a larger, more hydrophobic residue in place of the conformationally flexible glycine. This substitution may compromise tau's ability to properly interact with microtubules and other binding partners including HSP90AB1, GSK3B, SNCA, ANXA2, and DDX6. The variant's position suggests potential effects on tau's role in critical biological processes including axon development, amyloid fibril formation, and astrocyte activation, which are central to neurodegenerative pathology. ## Clinical Significance Current evidence regarding the clinical significance of the TAU G272V variant remains limited, with no comprehensive clinical characterization available in the provided data. The association with Alzheimer's disease suggests pathogenic potential, though definitive pathogenicity classification and population frequency data are not currently documented. The functional consequences likely involve disruption of normal tau homeostasis, potentially affecting phosphorylation patterns, aggregation propensity, and microtubule stabilization. The substitution from a small, flexible glycine to a larger valine may induce conformational changes that predispose tau to misfolding and aggregation, hallmark features of tauopathies. ## Therapeutic Landscape Analysis reveals an aggregation hotspot at residues 542-546 (score: 0.60), though this region is distal to the G272V mutation site. This finding suggests that therapeutic interventions targeting tau aggregation may need to consider multiple regions of the protein. Currently, no specific peptide inhibitors or small molecules targeting the G272V variant have been documented in the available data. The presence of AlphaFold structural predictions (9 structures identified) provides valuable resources for structure-based drug design approaches. Targeting the variant site or compensating for its structural effects through stabilization of native tau conformations represents a potential therapeutic strategy. ## Research Directions Critical knowledge gaps include: (1) comprehensive structural characterization of how G272V affects local and global tau conformation; (2) comparative analysis with well-studied tau variants (P301L, P301S) to understand shared versus unique pathogenic mechanisms; (3) experimental validation of aggregation kinetics and microtubule-binding affinity; (4) clinical penetrance and phenotypic variability studies; and (5) development of variant-specific therapeutic strategies. Leveraging available AlphaFold structures for molecular dynamics simulations could elucidate conformational consequences, while screening for compounds that stabilize the mutant protein or prevent pathological interactions with GSK3B and other kinases represents an actionable therapeutic avenue. --- ## Agent Findings ### Literature (1) - **2026-06-22:** None of the provided papers directly address the TAU G272V variant. While several papers provide valuable context about tau pathology mechanisms, MAPT gene regulation, and disease modeling approaches relevant to understanding tauopathies in general, they do not contain specific information about the G272V mutation associated with Alzheimer's disease. The radiomics papers are completely unrelated to protein variants or Alzheimer's disease biology. ### Clinical (1) - **2026-06-22:** ### Structural (1) - **2026-06-22:** AlphaFold structure update: Baseline check: 9 structure(s) found ### Synthesis (1) - **2026-06-22:** Synthesis of 1 findings (peptides): The TAU G272V variant associated with Alzheimer's disease shows promising druggability based on rece... --- *Generated by [Clarity Protocol](https://clarityprotocol.io)* **Data Sources:** - Structure predictions: AlphaFold via ColabFold - Clinical variant data: ClinVar, gnomAD - Disease associations: Open Targets Platform - Research findings: AI agents (PubMed, clinical databases)